GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cepheid (FRA:XEP) » Definitions » Piotroski F-Score

Cepheid (FRA:XEP) Piotroski F-Score : 0 (As of Apr. 26, 2024)


View and export this data going back to . Start your Free Trial

What is Cepheid Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Cepheid has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Cepheid's Piotroski F-Score or its related term are showing as below:


Cepheid Piotroski F-Score Historical Data

The historical data trend for Cepheid's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cepheid Piotroski F-Score Chart

Cepheid Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.00 3.00 5.00 4.00 5.00

Cepheid Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 5.00 5.00 6.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep16) TTM:Last Year (Sep15) TTM:
Net Income was -9.001 + -5.928 + -9.106 + -9.718 = €-33.8 Mil.
Cash Flow from Operations was 10.624 + -8.183 + 30.127 + 0.664 = €33.2 Mil.
Revenue was 134.945 + 130.012 + 129.941 + 141.213 = €536.1 Mil.
Gross Profit was 69.212 + 64.822 + 64.762 + 66.912 = €265.7 Mil.
Average Total Assets from the begining of this year (Sep15)
to the end of this year (Sep16) was
(731.952 + 748.547 + 734.983 + 748.868 + 754.995) / 5 = €743.869 Mil.
Total Assets at the begining of this year (Sep15) was €732.0 Mil.
Long-Term Debt & Capital Lease Obligation was €258.2 Mil.
Total Current Assets was €561.2 Mil.
Total Current Liabilities was €130.5 Mil.
Net Income was -19.276 + 0.837 + -14.906 + -20.405 = €-53.8 Mil.

Revenue was 106.664 + 122.557 + 118.035 + 112.68 = €459.9 Mil.
Gross Profit was 58.098 + 66.007 + 56.22 + 52.377 = €232.7 Mil.
Average Total Assets from the begining of last year (Sep14)
to the end of last year (Sep15) was
(595.403 + 643.589 + 752.007 + 734.074 + 731.952) / 5 = €691.405 Mil.
Total Assets at the begining of last year (Sep14) was €595.4 Mil.
Long-Term Debt & Capital Lease Obligation was €254.3 Mil.
Total Current Assets was €501.1 Mil.
Total Current Liabilities was €129.0 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Cepheid's current Net Income (TTM) was -33.8. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Cepheid's current Cash Flow from Operations (TTM) was 33.2. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep15)
=-33.753/731.952
=-0.04611368

ROA (Last Year)=Net Income/Total Assets (Sep14)
=-53.75/595.403
=-0.09027499

Cepheid's return on assets of this year was -0.04611368. Cepheid's return on assets of last year was -0.09027499. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Cepheid's current Net Income (TTM) was -33.8. Cepheid's current Cash Flow from Operations (TTM) was 33.2. ==> 33.2 > -33.8 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep16)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep15 to Sep16
=258.174/743.869
=0.34706917

Gearing (Last Year: Sep15)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep14 to Sep15
=254.297/691.405
=0.36779746

Cepheid's gearing of this year was 0.34706917. Cepheid's gearing of last year was 0.36779746. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep16)=Total Current Assets/Total Current Liabilities
=561.206/130.509
=4.30013256

Current Ratio (Last Year: Sep15)=Total Current Assets/Total Current Liabilities
=501.067/128.99
=3.88454144

Cepheid's current ratio of this year was 4.30013256. Cepheid's current ratio of last year was 3.88454144. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Cepheid's number of shares in issue this year was 73.158. Cepheid's number of shares in issue last year was 72.199. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=265.708/536.111
=0.49562124

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=232.702/459.936
=0.50594431

Cepheid's gross margin of this year was 0.49562124. Cepheid's gross margin of last year was 0.50594431. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep15)
=536.111/731.952
=0.73244011

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep14)
=459.936/595.403
=0.77247847

Cepheid's asset turnover of this year was 0.73244011. Cepheid's asset turnover of last year was 0.77247847. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+1+1+0+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Cepheid has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Cepheid  (FRA:XEP) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Cepheid Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Cepheid's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cepheid (FRA:XEP) Business Description

Traded in Other Exchanges
N/A
Address
Cepheid was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's product portfolio consists of tests, reagents and systems for the clinical and non-clinical markets. The Company's two systems are the GeneXpert and SmartCycler. The GeneXpert system, offers services in the clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Company faces competition from a number of companies that offer products to its target markets. Company has patents covering technologies of its own and has licensed technologies from others. In addition to patents, it rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop its competitive position with respect to intellectual property. In the Clinical market, its products are regulated as medical device products by the FDA and comparable agencies in other countries. For the Non-Clinical market, all of its products are being produced under ISO 13485 and Quality System Regulations.

Cepheid (FRA:XEP) Headlines

No Headlines